11:01 AM EDT, 09/18/2024 (MT Newswires) -- GSK (GSK) said Wednesday that it reached confidential settlements in two lawsuits in California claiming that its discontinued heartburn treatment Zantac (ranitidine) caused cancer.

The company said it does not admit any liability in either settlement and the cases will now be dismissed as to GSK.

GSK reiterated that after 16 studies since 2019, "the scientific consensus is that there is no consistent or reliable evidence" that ranitidine increases the risk of any cancer.

"GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders," the company said.

Price: 42.71, Change: +0.14, Percent Change: +0.34